In the first half of 2009, the company achieved an operating income of 6,543.8+0,599.3 million yuan, a decrease of 654.38+08% compared with the same period of last year, and a net profit of-6,543.8+0,654.38+0.72 million yuan, mainly due to the decline in the benefits of soybean deep processing business, and the company as a whole suffered a lot of losses.
Operating conditions of leading industries: 1. Real estate business: The "New Lake Pearl" project, which was developed by the company in 2006 and located at the 11th Avenue Street in Jingwei, Daoli District, Harbin, has been sold out except for the remaining underground parking spaces, and most of the profits gained from the project have been reflected in the company's performance in 2007 and 2008. The "New Lake Kangqiao" project, located in Daoli District, Harbin, was developed in 2008 and is the main project currently being sold by the company. Sales are good at present. However, due to the fact that part of the house purchase money received is not qualified for sales income, it is not reflected in the company's income and profits in the first half of 2009, which is one of the reasons for the company's losses in the first half of 2009. June 5438+October 2008 10, a real estate project located in Daoli District, Harbin, with an area of 8,727 square meters, was acquired by the company through bidding.
The planned building area is 68,245 square meters, and the building plan is being adjusted, and the land use planning permit is being processed. It is planned to start construction in June this year 10, and complete it by the end of 20 1 1. 2. Pharmaceutical business: In the first half of 2009, Harbin White Swan Pharmaceutical Group Co., Ltd. (referred to as White Swan Pharmaceutical for short) realized an operating income of 2210.2 million yuan and a net profit of10.53 million yuan. Since April this year, White Swan Pharmaceutical began to transform the interferon α-2b project with a budget investment of 7.09 million yuan. As of the date of completion of this report, the project is progressing normally. It is estimated that the project transformation will be completed in February 20 10. After the project is put into production, it can produce 6 million interferons every year, with an annual profit of more than 2 million yuan.
On June 24th, 2009, the company signed an equity transfer agreement with the State-owned Assets Supervision and Administration Commission of Jiamusi Municipal People's Government (hereinafter referred to as "Jiamusi SASAC"), and the company transferred all its equity of RMB 654,380,500 to Jiamusi SASAC at a transfer price of RMB 8,654,380,370,644.00. Before the transfer, the company * * * held 5 1% equity of Harbin Hi-Tech Jiamusi Chinese Medicine Co., Ltd. By the end of 2008, the company's shareholders' equity was 8.56 million yuan, and the company's operating income in 2008 was12.64 million yuan and its net profit was 570,000 yuan. On July 29th, the company received all the money paid by Jiamusi SASAC, and the equity transfer has been completed. 3. Soybean deep processing business: The production and sales of Harbin Hi-Tech Soybean Food Co., Ltd. are relatively stable, but due to the high price of raw materials in stock and the rising price of production steam, the production cost of the enterprise has increased. Affected by the above factors, the company achieved net profit during the reporting period.